A potentially promising treatment of metastatic cancer is the systemic delivery of oncolytic adenoviruses. This requires engineering viruses which selectively replicate in tumors. We have constructed such an oncolytic adenovirus, OAS403, in which two early region genes are under the control of tumor-selective promoters that play a role in two key pathways involved in tumorigenesis. The early region E1A is controlled by the promoter for the E2F-1 gene, a transcription factor that primarily upregulates genes for cell growth. The E4 region is under control of the promoter for human telomerase reverse transcriptase, a gene upregulated in most cancer cells. OAS403 was evaluated in vitro on a panel of human cells and found to elicit tumor-selective cell killing. Also, OAS403 was less toxic in human hepatocyte cultures, as well as in vivo when compared to an oncolytic virus that lacked selective E4 control. A single intravenous injection of 3 Â 10 12 vp/kg in a Hep3B xenograft mouse tumor model led to significant antitumor efficacy. Additionally, systemic administration in a pre-established LNCaP prostate tumor model resulted in over 80% complete tumor regressions at a tolerable dose. Vector genome copy number was measured in tumors and livers at various times following tail vein injection and showed a selective time-dependent increase in tumors but not livers over 29 days. Furthermore, efficacy was significantly improved when OAS403 treatment was combined with doxorubicin. This virus holds promise for the treatment of a broad range of human cancers including metastatic disease.
T he replication of adenoviruses (Ad) in human cells leads to cell destruction, virus release, and virus spread. Control of adenoviral replication using tumorselective promoters to limit the expression of essential early viral genes, such as E1A, has been demonstrated to result in viruses with potential for therapeutic applications. [1] [2] [3] [4] Since replication of Ad requires E1A gene expression for transactivation of other essential viral genes, 5 control of this transcription unit contributes significantly to control of the entire viral life cycle. The concept of controlling adenoviral early genes with tumorselective promoters has been employed by several investigators using a variety of tumor selective promoters such as alpha-fetoprotein, prostate specific antigen, MUC1, osteocalcin, and L-plastin. 2, [6] [7] [8] [9] Clinical trial data also suggest the utility of oncolytic Ads for the treatment of cancer.
Previously, we described the oncolytic Ad called Ar6pAE2fF, in which the E2F-1 promoter controls expression of E1A. 4 This oncolytic Ad was safe and efficacious when delivered intratumorally. The adenoviral E4 region, like E1A, is necessary for viral replication. In addition, the expression of E4 proteins is toxic in vivo. 15, 16 Ad E4 encodes genes that potentiate a variety of adenoviral functions that influence cell toxicity and host immune responses and are required for viral replication. 15, 17 Owing to their essential importance, tumorselective transcriptional control of these genes may offer an additional advantage. Replacing the native E4 promoter with a heterologous tumor-selective promoter is expected to augment tumor-selective control. Thus, E4 control in combination with E1A control may allow safe intravenous (i.v.) delivery of oncolytic Ads. We have constructed a dual controlled oncolytic Ad, OAS403, in which the tumor-selective expression of both the E1A and E4 adenoviral early genes is accomplished by replacing the nonselective, native promoters with tumor-selective promoters from the human E2F-1 and human telomerase reverse transcriptase (hTERT) genes, respectively. The E2F-1 promoter is expected to be derepressed in all tumor cells that have a defective Rb pathway (approximately 85% of all tumor types). The hTERT promoter is expected to be active in tumors with upregulated telomerase activity (approximately 90% of all human cancers).
The retinoblastoma tumor-suppressor protein Rb is a nuclear phosphoprotein critical for cell-cycle regulation. 18, 19 During tumorigenesis, disruption of the Rbpathway is common and leads to the loss of Rb binding to the transcription factor E2F. 20 This results in an apparent increase in transcriptionally active or ''free'' E2F in tumor cells. The abundance of free E2F in turn results in highlevel expression of E2F-responsive genes in tumor cells, including the E2F-1 gene itself. 21, 22 Previously, we have shown that Ad vectors utilizing the E2F-1 promoter selectively killed cells with disruptions in the Rb pathway. 4 The hTERT gene has been previously shown to be selectively expressed in the majority of human cancers. [23] [24] [25] [26] [27] [28] Furthermore, the hTERT promoter has been shown to confer tumor-selective expression of the linked gene in plasmids and Ad constructs. [28] [29] [30] [31] [32] [33] Oncolytic adenoviruses utilizing the hTERT promoter to control Ad early region genes have also been previously described. [34] [35] [36] By using both the E2F-1 promoter and the hTERT promoter to control different early region genes in the same Ad vector, we have constructed an oncolytic Ad which is active in a broad panel of tumor types and is safe and effective when delivered systemically.
We show here that OAS403 kills tumor cells through the tumor-selective expression of toxic viral proteins, viral replication, and cytolysis. OAS403, like other oncolytic Ads, is also predicted to sensitize tumor cells to chemotherapy, cytokines, and lysis by cytotoxic T lymphocytes. In this report, we demonstrate that adding E4 control to an oncolytic Ad with E1A control improves tumor selectivity as measured in vitro by cytotoxicity assays and in vivo allows for tolerable and efficacious systemic administration as determined in murine models. In addition to antitumor efficacy, we were able to demonstrate tumor-selective expression of both E1A and E4, as well as tumor-selective viral replication following a single i.v. injection to tumor-bearing nude mice. These results demonstrate that oncolytic Ads engineered to contain tumor-selective promoters can selectively express early genes, replicate in tumors and mediate an antitumor effect with a high therapeutic index.
Materials and methods

Cells
AE1-2A (also called S8) is an Ad-complementing cell line derived from A549 lung carcinoma cell line and used to produce adenoviral vectors. 16 These cells were cultured in Richter's media containing 5% heat-inactivated fetal bovine serum (FBS). The human tumor cell line Hep3B (Hep 3B2.1-7, ATCC #HB-8064), a hepatocellular carcinoma (HCC) line, 37, 38 was used for in vitro studies as well as in vivo in a murine subcutaneous xenograft tumor model. These cells were cultured in EMEM containing 10% FBS. The additional human tumor cell lines used in this report were: the prostate carcinoma metastases cell lines LNCaP (ATCC #CRL-1740); C4-2 an androgenindependent subline from LNCaP cells found to be highly tumorigenic and metastatic to bone, received from LW Chung, University of Virginia, Charlottesville, VA; 39 PC-3M2AC6, a luciferase-expressing subclone of PC3 M cells, and VCaP cells derived from a vertebral metastatic lesion, received from Ken Pienta, University of Michigan, Ann Arbor, MI. 40 The colorectal adenocarcinoma cell lines used were SW620 (ATCC #CCL- Except as noted, tissue culture reagents were obtained from Life Technologies (Rockville, MD). FBS was purchased from BioWhittaker (Walkersville, MD). LNCaP and C4-2 cells were grown in RPMI medium plus 10% FBS and supplemented with glutamine, nonessential amino acids, sodium bicarbonate, and sodium pyruvate. PC-3M2AC6 were grown in RPMI medium plus 10% FBS. VCaP cells were grown in Dulbecco's modified Eagle medium plus 10% FBS. All other cell lines and primary cell cultures were grown in the supplier's recommended media.
Primary human hepatocytes were purchased from In Vitro Technologies (Baltimore, MD) and cultured in Hepatocyte Culture Media (HCMt, BioWhittaker/Clonetics Inc, San Diego, CA). Amphotericin B and penicillin/streptomycin were added to the HCM at final concentrations of 250 ng/ml, 10 U/ml, and 10 mg/ml respectively. Cells were maintained at 371C with 5% CO 2 in a humidified incubator, and media was replaced every 2 days.
Plasmids and viruses
The genomic structure of the oncolytic Ad OAS403 is shown schematically in Figure 1 . The backbone is based on human Ad serotype 5 and is similar to Ar6pAE2fE3F, which was described previously and is referred to as E2F-E3. 4 These oncolytic Ads have the E2F-1-responsive promoter inserted upstream of the E1A transcription unit in place of the endogenous promoter; the packaging signal has been moved to the right end and the SV40 early polyadenylation (pA) signal has been inserted between the left ITR and the E2F-1 promoter to prevent nonspecific read-through from enhancer elements in the ITR. Another oncolytic Ad used in these studies is Ar13-pAE2fF, which is identical to Ar6pAE2fE3F except that a lox site in the E3 region has been removed to render the E3 region identical to wild-type Ad5. In this report, Ar13pAE2fF is referred to as E2F-E1A (Fig 1) . In OAS403, the Ad E4 promoter and E4 transcription start site have been deleted and replaced with a 248-bp promoter fragment from hTERT. The hTERT promoter fragment was isolated from plasmid pGRN316 (obtained from Geron Corp.), and the sequence includes À248 to þ 1 relative to the ''A'' in the ATG codon (nucleotides 2249-2496 in GenBank accession number E36796). Additional control viruses used include wild-type Ad5 and E1A-deleted Ad Addl312. 41 All cloning steps were performed on plasmids that contained Ad sequences. Modified sequences were incorporated into the Ad genome by homologous recombination. 42, 43 The left and right ITRs, E2F-1 promoter, SV40 pA, the E1A adenoviral gene, hTERT promoter, a portion of the adenoviral E3 region (bp 29,994-30,575) and c of the viral genome were sequenced by automated cycle sequencing using dye terminators and were found to be as predicted.
Recombinant viruses were generated following transfection of linearized plasmid into AE1-2A cells as previously described. 4 Viruses were purified on CsCl gradients and viral particle (vp) titers determined spectrophotometrically, as previously described. 44, 45 Cytotoxicity assays Cytotoxicity on a panel of tumor and nontumor cells was determined by exposing cells to serial dilutions of virus for 7-10 days, after which an MTS cytotoxicity assay (CellTiter 96 s AQueous Non-Radioactive Cell Proliferation Assay, Promega, Madison, WI) was performed and a lethal dose-50 percent (LD 50 ) value in particles per cells (ppc) was calculated as previously described. 4 Cytotoxicity on primary human hepatocytes was determined by LDH release assay (CytoTox s 96 NonRadioactive Cytotoxicity Assay, Promega, Cat. No. G1780). Primary human hepatocytes plated in 12-well collagen-coated plates at a concentration of approximately 1.5-1.8 Â 10 5 cells/well were infected with the indicated adenoviral Ads at 1, 10, and 50 ppc in 200 ml infection media (HCM containing 2% FBS) at 371C for 1 hour with rocking. Then 2 ml growth media was added to each well and the cells were incubated at 371C with 5% CO 2 in a humidified incubator. After 5 and 7 days post infection, the growth medium was collected and LDH in the supernatant was measured spectrophotometrically. Cell lysates for determination of maximal cellular LDH were simultaneously collected by three cycles of freezethawing. The cytotoxicity at each dose and time point was determined in triplicate wells, except where indicated. Percent cytotoxicity was calculated as the ratio of LDH units in supernatant over maximal cellular LDH plus supernatant LDH: % Cytotoxicity ¼ LDH units in culture supernatantÂ100 Sum of LDH units in supernatant and cell lysate
Animal studies
All animals were cared for and maintained in accordance with applicable US Animal Welfare regulations under an approved Institutional Animal Care and Use Protocol in Genetic Therapy Inc.'s. animal facility, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care.
For evaluation of Ad-mediated hepatotoxicity, 5-weekold male C.B-17/lcr-SCID mice (Harlan Sprague Dawley, Indianapolis, IN) were used as previously described. 4 A dose of 4 Â 10 12 viral particles per kilogram (vp/kg) of each test Ad was administered i.v. on study day 1 (SD1) into the lateral tail vein (n ¼ 10/group). A control group of animals (n ¼ 10) was injected with an equivalent dose volume (10 ml/kg) of the Hanks buffered saline solution (HBSS) vehicle. Body weights were measured on SD1, 2, 3, 4, 8, and 15. Clinical observations for morbidity and mortality were recorded daily. Serum was collected by orbital sinus bleeds on SD4 (n ¼ 10/group) and SD15 (n ¼ 5/group). Serum was analyzed by AniLytics, Inc (Gaithersburg, MD) for selected clinical chemistry parameters including aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase (CPK), and creatinine (CREAT). Five mice per group Figure 1 Oncolytic adenovirus constructs. Schematic representation of the Ad5-based oncolytic Ads used in this report: E2F-E3, E2F-E1A, and OAS403. In E2F-E3, the E3 region contains a lox site. In E2F-E1A and OAS403, the E3 region is wild type. In all the three viruses, the packaging signal (C) has been moved to the right end of the genome, the native E1A promoter replaced with the E2F-1 promoter (E2F Pr), and the SV40 early polyadenylation signal (pA) inserted between the left ITR and the E2F-1 promoter. In OAS403, the native E4 promoter has been replaced with a 248-bp fragment of the hTERT promoter (hTERT Pr). This schematic is not to scale.
were killed on SD4. All the remaining mice were killed on SD15. At these scheduled necropsies, livers were collected and portions were frozen on dry ice for DNA analysis, or frozen in liquid nitrogen for RNA analyses.
A Hep3B xenograft mouse tumor model was used to assess the effects of OAS403 following a single i.v. administration. Hep3B human hepatocellular carcinoma cells (1 Â 10 7 cells/100 ml of HBSS) were implanted subcutaneously on the right flank of female athymic outbred nu/nu mice (Harlan, 6-8 weeks old). Tumor measurements were recorded twice weekly in two dimensions using calipers. Tumor volume was calculated using the formula length Â width 2 Â p/6. When tumor volumes were between 91.6 and 218.5 mm Virus distribution and expression of E1A and E4 genes was determined 3 days after Ad administration in mice selected from four groups, HBSS control, low, mid and high dose of OAS403 (n ¼ 3 per group). Tumor and normal tissues, including liver, kidney, lung, bone marrow, brain, spleen, and ovary, were collected. DNA was extracted from each tissue and quantitative PCR performed for the adenoviral hexon gene. Tissues that were positive for hexon DNA (livers and tumors) were evaluated for E1A and E4 expression using RT-PCR methods.
Daily observations for morbidity and moribundity were performed. Animals were killed according to GTI guidelines for the ethical treatment of animals when tumors exceeded a volume of 2000 mm 3 or if the physical condition of the animal warranted intervention as prescribed by facility policies for humane care. Body weights were collected 1 and 3 days after dosing (SD2 and SD4, respectively), and then weekly for the duration of the study. Clinical pathology analyses were performed by AniLytics, Inc (Gaithersburg, MD). Blood was collected by orbital bleed from five mice pergroup at SD2, 4, 8, 15, and 29, and processed to serum for measurement of serum enzymes including AST, ALT, CPK, and CREAT. A complete blood cell count (CBC) was also performed on whole, unclotted blood collected from five mice per group at SD4, 8, 15, and 29 and platelet levels enumerated.
In a second experiment, 33 mice with subcutaneous Hep3B tumors (mean tumor volume between 89.6 and 212.5 mm 3 ) were injected via tail vein with Ad at 3 Â 10 12 vp/kg. Tumors and livers were collected at 4 hours, 24 hours, 3 days, 7 days, 14 days, and 28 days postinjection and total DNA isolated for hexon gene PCR to determine Ad copy numbers per cell (n ¼ 5 per timepoint). Tumors and livers from three mice were collected prior to Ad injection as untreated controls.
Efficacy in combination with chemotherapy was evaluated in the Hep3B xenograft tumor model using a , mice were sorted into groups (n ¼ 12/group) and treated via tail vein injection with either HBSS, Addl312 (3 Â 10 12 vp/kg), or OAS403 (3 Â 10 12 vp/kg) in a dose volume of 10 ml/kg. Tumor volumes were measured weekly as described above.
Real-time PCR
Total DNA was isolated from frozen tissues using the Qiagen Blood and Cell Culture DNA Midi or Mini Kits (Qiagen Inc, Chatsworth, CA). Quantitative real-time PCR was carried out to determine adenoviral DNA content in mouse tissues using hexon gene specific primers as described previously. 46 In the SCID mouse studies, the expression level of E1A and E4 in liver tissue was normalized to viral DNA copy using DNA isolated from mouse liver as described. 46 In the xenograft tumor-bearing athymic nude mouse model, total E1A and E4 levels per cell in tumor and liver tissue are reported.
Quantitative reverse-transcriptase PCR (RT-PCR) analysis for E1A and E4 expression was performed as previously described for E1A. 4 Primers specific for the Ad E1A were described previously. 4 Sequences of the E4 probe and primer set are targeted to a sequence common to all spliced transcripts and are shown below:
Amplification was performed in a reaction volume of 50 ml under the following conditions: 20 ml of sample cDNA, 1 Â Taqman Universal PCR Master Mix (Applied Biosystems), 300 nM forward primer, 900 nM reverse primer, and 100 nM E1A or E4 probe. Thermal cycling conditions were: a 2-minute incubation at 501C, a 10-minute 951C activation step for the Amplitaq Gold, followed by 35 cycles of successive incubation at 951C for 15 seconds and 601C for 1 minute. Thermal cycling was carried out with a 7700 Sequence Detection System (Applied Biosystems). To assess RNA input (endogenous control), 10 ml of a 1:1000 dilution of each cDNA was amplified using a Pre-Developed Taqman Assay Reagent 18S kit (Applied Biosystems) as per the manufacturer's instruction. Data were collected and analyzed using the 7700 Sequence Detection System software v. 1.6.3 (Applied Biosystems). Relative levels of E1A and E4 were determined based on a plasmid curve generated with dilutions from 1,500,000-15 copies. For endogenous control, input RNA was assessed by using an RNA standard curve. A standard curve consisting of 10-fold dilutions from 1 mg to 1 ng of cellular RNA (RNA from human non-small-cell carcinoma cell line NCI-H460 was used) was reverse transcribed along with each set of test samples. In all, 10 ml of a 1:1000 dilution of each standard curve point cDNA was amplified using Applied Biosystems Pre-Developed Taqman Assay Reagent 18S kit according to the manufacturer's instructions. Amplifications of E1A, E4, and 18S RNA were performed in duplicate and the average value for each was reported.
Results
The oncolytic Ads used in this publication are shown in Figure 1 . The common features of all three oncolytic Ads are: (1) the packaging signal is moved to the right end; (2) the SV40 early polyadenylation signal is inserted downstream of the left ITR to prevent nonspecific expression of E1A; and (3) the E2F-1 promoter has been inserted in place of the native E1A promoter to control E1A. E2F-E1A is identical to the previously described E2F-E3, 4 except that a lox site has been removed to restore the E3 region. OAS403 is identical to E2F-E1A, except that the native E4 promoter has been replaced with a 248-base pair (bp) fragment of the hTERT promoter.
Cytotoxicity in vitro
Cytotoxicity is one measure of the potency and selectivity of oncolytic Ads. We measured the ability of OAS403 to kill both tumor cell lines and nontumor primary cells using an in vitro cytotoxicity assay based on the Promega CellTiter 96
s AQ ueous Non-Radioactive Cell Proliferation Assay. We compared the cytotoxicity profile of OAS403 with the single-promoter Ad (E2F-E1A), a positive control wild-type virus (Ad5), and a negative control replication-defective virus (Addl312). 41 Cytotoxicity assays were performed as previously described. 4 Dose-response curves for three tumor cell lines (Hep3B, SW480, and PC3M2AC6) and for one nontumor cell line, Wi38, are shown in Figure 2 . In each of the tumor cell lines, the potency of OAS403 is within one log of either E2F-E1A or Ad5, albeit lower. On the nontumor cell lines, OAS403 is much more highly attenuated than Ad5 or E2F-E1A with an LD 50 very similar to the negative control, replication-defective virus, Addl312. In fact, OAS403 is at least 1000-fold less cytotoxic than Ad5 in Wi38 cells, while there is less than a 10-fold difference in LD 50 between E2F-E1A and Ad5 on this nontumor cell line.
A quantitative evaluation of cytotoxicity was determined by calculating the LD 50 values from the doseresponse curves in a larger panel of cell lines (Fig 3) . To evaluate tumor selectivity of cell killing, the LD 50 of OAS403 was compared to that of Ad5 within the same cell line to control for differences in infectivity. A relative LD 50 (LD 50Ad5 /LD 50OAS403 ) equal to 1 indicates a potency equivalent to Ad5. For most tumor cell lines tested, OAS403 is less potent than Ad5. However, it is more selective for tumor cell killing since the relative LD 50 of OAS403 is higher in tumor cells than in the nontumor cells, Wi38, MRC-5, HRE, and HAEC (Fig 3) .
Cytotoxicity in cultured primary human hepatocytes
Upon systemic administration, Ad vectors can cause extensive toxicity in the liver. Therefore, an evaluation of cytotoxicity was carried out in cultures of primary human hepatocytes. Data shown are results from a single donor, but additional donors gave similar results (data not shown). Cells were transduced with 1, 10, and 50 particles per cell (ppc) of Ad5, Addl312, OAS403, and E2F-E1A. Cytotoxicity was measured at 5 and 7 days post-infection by LDH release assay. The data shown in Figure 4 illustrate that at 1 and 10 ppc 5 days post infection, the cytotoxicity from OAS403 and E2F-E1A was low and comparable to the level of cell killing seen for Addl312, while Ad5 caused significant cytotoxicity at all the three doses. At 50 ppc, the single promoter-controlled oncolytic Ad E2F-E1A elicited 13.770.6% cytotoxicity, which was significantly higher than the 870.8% cytotoxicity seen for OAS403 (Po0.05 by t-test; Figure 4 ). At 7 days post infection, cells treated with Ad5 were fully lysed and percent cytotoxicity could not be evaluated. The difference in toxicity between the single-and dual-promotercontrolled oncolytic Ads at 7 days was more pronounced than at 5 days, with E2F-E1A eliciting a higher percent cytotoxicity than OAS403 (2571 vs 1071% at 10 ppc; Po0.001 by t-test). These results indicate that the additional regulation provided by the hTERT promoter in OAS403 may reduce the cytotoxicity in non-tumor cells by restricting the expression of the E4 region genes. Notably, at 50 ppc, Addl312 caused more cytotoxicity (34% from single replicate) than OAS403 (1670.5%), which may reflect the toxicity from unrestricted expression of the E4 region by the Addl312 virus.
Toxicity in SCID mice
Previously, we described an in vivo model system used to assess the effectiveness of promoters to control replication of oncolytic Ads in nontarget tissues on the basis of E1A expression and selected toxicological parameters. 4 In those studies, the single promoter-controlled oncolytic Ad, Ar6pAE2fF, had reduced E1A-related hepatotoxicity relative to a wild-type virus, Addl327, following a single i.v. injection in SCID mice. 4 We have utilized this model to evaluate the effects of single-vs dual-promoter control oncolytic Ads in SCID mice treated intravenously with OAS403 and E2F-E3.
In previous studies, we used a dose of 6.25 Â 10 11 vp/kg to demonstrate the benefits of E2F-1 promoter control of E1A. 4 Here, a higher dose of 4 Â 10 12 vp/kg was necessary to distinguish improvements between single-and dualpromoter-controlled oncolytic Ads. In all, 10 mice per group were each treated intravenously with 4 Â 10 12 vp/kg of OAS403, E2F-E3, a negative control Ad Addl312, or HBSS vehicle control. Five animals were killed on SD4 to collect livers for molecular analysis. The remaining mice were killed on SD15 and tissues collected. Effects of E1A-and E4-related hepatotoxicity were evaluated by monitoring serum liver enzymes at indicated times. Viral DNA replication was measured by hexon gene-specific PCR to quantitate Ad genome copy number in livers on SD4. Early gene transcriptional control was evaluated by determining E1A and E4 transcript levels by RT-PCR on SD4. All mice were observed daily for mortality and moribundity. No morbidity was seen in the HBSS, Addl312 or OAS403 treatment groups. In contrast, all mice treated with E2F-E3 were moribund by SD4 and were killed. Individual body weights were collected from five mice per group at the indicated times. Relative to SD1, all treatment groups showed an initial loss of body weight at SD2 (Fig 5) . The HBSS-and Addl312-treated animals subsequently gained weight over the course of the study, while E2F-E3-treated animals lost weight steadily between SD1 and SD4, at which time they became moribund and were terminated. In contrast, the OAS403 treatment group gained body weight after the initial loss at SD2, and the difference in mean body weight change for this group was not significant compared to the HBSStreated group.
Selected clinical chemistry parameters were monitored by bleeding five mice per group on SD4 and SD15 (except for E2F-E3-treated mice which did not survive to SD15 and were only evaluated on SD4). Serum levels of ALT, AST, CPK, and CREAT were measured in two separate studies. CPK and CREAT levels were not different between any treatment group at SD4 or SD15, indicating that there was no overt toxicity in skeletal muscle, cardiac muscle, brain, or kidney (data not shown). The OAS403 treatment group had significantly elevated levels of both AST and ALT on SD4 relative to HBSS-treated mice (Table 1) . However, these levels were significantly lower than the E2F-E3-treated mice (Table 1) . On SD15, levels of both AST and ALT in OAS403-treated animals remained significantly elevated relative to HBSS-and Addl312-treated mice (Table 1) . Comparisons between OAS403 and E2F-E3 treatment groups at this timepoint were not possible since all of the E2F-E3-treated animals were terminated on SD4 because of moribund condition.
The Ad genome copy number was measured at SD4 in the livers of mice treated with the replication-selective 
Day 7 Addl312
OAS403 E2F-E1A Figure 4 Cytotoxicity in cultured primary human hepatocytes. Primary human hepatocytes were transduced with OAS403, E2F-E1A, wild-type Ad5 or E1A-deleted virus Addl312 at 1, 10, and 50 ppc. Cellular LDH levels were measured 5 and 7 days after transduction. The percent cytotoxicity was calculated as described in Materials and methods. The mean percent cytotoxicity þ SD at each dose and time point was determined in triplicate wells. Where no error bar is indicated, duplicate wells were averaged. Ad5-treated hepatocytes could not be analyzed 7 days post-transduction because they were fully lysed. OAS403 and E2F-E3, and the replication-defective Addl312. On SD4, genomic DNA was isolated from a portion of the liver in five animals per group. Quantitative PCR analysis for hexon was performed and the average number of Ad genome copies per cell calculated (Table 2) . Mice treated with the replication-defective Addl312 had only 19 copies per cell, while mice treated with E2F-E3 averaged 1522 copies per cell. In contrast, the OAS403 treatment group had a significantly lower mean value of 232 copies per cell (Table 2 ; Po0.05). These differences in copy number may reflect either differences in viral DNA persistence or differences in the ability of these viruses to replicate in the liver. In order to better understand the relationship between hepatotoxicity, viral DNA copy number, and control of E1A and E4 expression, we analyzed the levels of early gene mRNA expression in the liver. The relative levels of E1A on a per Ad genome basis were similar between E2F-E3-and OAS403-treated mice (Table 2) . Since the E1A region in both Ads is under the control of the E2F-1 promoter, this result was expected. E4 expression levels were also measured ( Table 2 ). E2F-E3 and Addl312 both have the native E4 promoter, and mice treated with these Ads showed no difference in relative E4 expression levels (1787 vs 2169 RNA units). However, mice treated with OAS403 showed a significant reduction in E4 RNA levels (272 RNA units) compared to either E2F-E3 or Addl312 (Po0.05).
Efficacy and tolerability in Hep3B xenograft tumor model
A xenograft model of hepatocellular carcinoma was used to assess the efficacy of OAS403 following a single systemic administration. Female nude mice with preestablished subcutaneous Hep3B tumors were treated with a single i.v. injection of OAS403 at three different doses, 1.5 Â 10 12 , 3.0 Â 10 12 , or 4.5 Â 10 12 viral vp/kg in a final volume of 10 ml/kg. All three doses showed a significant inhibition in tumor growth when compared to HBSS-injected controls (Fig 6a; Po0.05 on SD18) . All the three doses also showed a significant inhibition in tumor growth when compared to Addl312-injected controls (Fig 6a; Po0.05 on SD25) . No dose response in antitumor efficacy was observed over this relatively narrow dose range, but broader dose ranges did demonstrate a dose response in this model (data not shown).
Tolerability was assessed by monitoring body weights, clinical observations, and clinical pathology. There was a general trend of body weight loss 1 day after injection in all treatment groups that appeared to be dose-dependent; there was a 6% decrease in the high-dose group and 3% decrease in the Addl312-treated group, which was not statistically significant. Body weights recovered in all groups after 1 week (data not shown).
Complete blood cell counts were performed on SD4, 8, 15, and 29. A dose-dependent decrease in platelet counts was observed on SD4 in animals injected with OAS403 as compared to HBSS controls (Fig 6b) . Platelet counts in all treatment groups rebounded to levels higher than the control group by SD8, and remained at control levels for the remainder of the study. No other hematology parameters were significantly affected.
A selected set of serum chemistry parameters was evaluated on SD2, 4, 8, 15, and 29. The most prominent change occurred in AST levels in animals injected with the highest dose (Fig 6b) . The increase in AST in the highdose group was more pronounced at SD4 and SD8. The increase in AST levels on SD29 in all treatment groups may reflect the increase in the Hep3B hepatocellular carcinoma tumor burden in all animals at this late timepoint. Results for serum ALT were similar to AST, while other chemistry parameters evaluated were not significantly different from controls (data not shown).
At 3 days after i.v. dosing, on SD4, Ad genome copies per cell in selected tissues were determined by Q-PCR assay. Tissues from HBSS-treated control animals were negative for Ad DNA (Table 3 ). In OAS403-treated mice, tumors contained high levels of Ad genome copies (Table 3) . Copy number in the tumors did not increase in a dose-dependent manner, which is consistent with the observed lack of antitumor dose response (Fig 6a,  Table 3 ). Of the normal tissues evaluated, liver had the highest copy number with a marked increase at the highest dose (Table 3 ). All other tissues analyzed contained low but measurable levels of Ad DNA (Table 3) . Ad genome copies in the tumors of low-and mid-dose-treated mice were higher than in the liver or any other organ. Animals were treated on SD1 with HBSS or with 4 Â 10 12 vp/kg of the indicated Ad. Serum was collected on SD4 (n ¼ 10 mice) and SD15 (n ¼ 5 mice). The mean ALT or AST values in each treatment group7SD are shown. *Po0.05 vs HBSS (t-test on log 10 -transformed data). **Po0.05 vs E2F-E3 (t-test on log 10 -transformed data). Animals were treated on SD1 with HBSS or with 4 Â 10 12 vp/kg of the indicated Ad. RNA and DNA were isolated from the livers of five mice per group on SD4. E1A and E4 RNA levels shown are mean7SD RNA expression units per Ad genome copies as determined by semiquantitative RT-PCR assay using E1A-or E4-specific primers. Hexon values are mean7SD of Ad copies per cell as determined by hexon DNA PCR.
Expression of adenoviral E1A and E4 genes was analyzed in tumors and livers (Table 3) . At the low and mid dose, OAS403-treated mice had much higher E1A and E4 expression levels in tumor compared to liver. At the high dose, the levels of E1A and E4 expression were dramatically higher in liver, which is consistent with the high copy number seen in liver, at this dose (Table 3) .
Kinetics of replication in Hep3B xenograft model
Ad genome copy number in tumors and livers was monitored by hexon DNA-specific Q-PCR at various timepoints after i.v. delivery of OAS403 in Hep3B tumorbearing mice. The dose of OAS403 used in this study (3 Â 10 12 vp/kg) was the mid dose used in the prior doseresponse efficacy study shown in Table 3 . On study day 4, the number of Ad genomes per cell isolated from liver and tumor were comparable in these two independent experiments (9.171.3 vs 10.674.7 in liver and 45.8733.2 vs 118.57118 in tumor). Samples from untreated animals were negative for Ad DNA, as expected. In tumors, the copy number was low but detectable at the early timepoints and then increased significantly at the 24-hour timepoint (Fig 7) . The highest copy number in tumors was detected at 14 days (666.87199.3 copies per cell), a value significantly higher than the previously tested timepoint, 7 days. In livers, the highest copy number was detected at 4 hours (73.6717.7 copies per cell), the earliest timepoint assessed, and then declined by 24 hours. After 24 hours, the copy number in liver persisted at low levels (10. , and 29 and processed to serum for measurement of ALT, AST, ALP, CPK, and creatinine. A complete blood cell count (CBC) was performed on whole, unclotted blood collected from five mice per group. Platelet counts and AST levels from group means þ SEM are shown, with n ¼ 5/group. copies per cell). The relative level of Ad genome in tumor compared to liver changed dramatically over the course of the study. At 14 and 28 days, copy number was greater than 25-fold higher in tumor than in liver, suggesting that Ad DNA replication was occurring in the tumor.
Efficacy in LNCaP prostate cancer xenograft model
A single i.v. injection of OAS403 at 3 Â 10 12 vp/kg in male SCID mice bearing pre-established LNCaP prostate carcinoma xenograft tumors leads to a dramatic antitumor response with 83% (10 of 12) of the OAS403-treated mice having complete tumor regressions by SD45. The nonreplicating control virus Addl312 did not inhibit tumor growth in this model (Fig 8) .
Efficacy in combination with Doxil s (Hep3B Model)
Antitumor efficacy in combination with chemotherapy was evaluated in a Hep3B tumor model using OAS403 and a liposome formulation of doxorubicin called Doxil s . Treatment of Hep3B-tumor-bearing nude mice with Doxil s alone led to significant tumor inhibition compared to HBSS control (Po0.001 on SD21; Figure 9 ). Treatment with OAS403 only at 1 Â 10 12 vp/kg also led to significant tumor inhibition compared to HBSS control (Po0.005 on SD21; Figure 9 ). The combination treatment of OAS403 with Doxil s elicited significantly improved antitumor efficacy compared to either agent alone (Po0.01 on SD21; Figure 9 ). The low dose of OAS403, 6 Â 10 11 vp/kg, in combination with Doxil s gave similar efficacy as the high dose, 1 Â 10 12 vp/kg, in combination with Doxil s (Fig 9) . In the high dose plus Doxil s combination group, three of 10 mice had complete tumor regressions by SD28, which were sustained to the termination of the study (SD73). In the low dose plus Doxil s combination group, two of 10 mice had complete regressions by SD28, which were sustained to the termination of the study (SD73).
Discussion
We have modified an earlier generation oncolytic Ad (E2F-E1A), which utilizes the E2F-1 promoter to control Tissues were collected from mice (n ¼ 3) on SD4 after treatment with HBSS or OAS403 at a low dose (1.5 Â 10 12 vp/kg), mid dose (3 Â 10 12 vp/kg), or high dose (4.5 Â 10 12 vp/kg). To measure Ad genome copies per cell, total DNA was isolated from tissues and molecular analysis was done by hexon gene-specific DNA PCR. Results are mean hexon copy number per cell7SEM. BM is bone marrow. Values for brain represent a single sample or the mean of two samples. Total RNA was isolated from Hep3B tumors and livers. Semiquantitative RT-PCR assays using E1A-or E4-specific primers was performed. E1A and E4 values represent mean RNA expression units7SEM normalized to 18S RNA. RNA values for tumor at low dose represent the mean of two samples. E1A, by operably linking expression of the adenoviral E4 region to the human telomerase reverse transcriptase promoter (hTERT) (Fig 1) . This oncolytic Ad, OAS403, is expected to be active in tumors that have a disruption of the Rb pathway and upregulation of telomerase expression. These defects are represented in a majority of human cancers. We tested OAS403 for selectivity, safety, and efficacy in a wide panel of in vitro and in vivo assays, and showed that adding control of E4 gene expression increased tumor selectivity in vitro, decreased toxicity in vivo, and allowed for safe and effective systemic administration in mouse tumor models.
The in vitro cytotoxicity of oncolytic Ads in tumor cells as measured by the MTS assay can be used to make comparisons in their cytolytic and replicative capacity. We have shown previously that maximal and selective cytotoxicity measured by this assay is dependent on virus replication as well as E1A expression. 4 The mechanism of adenovirally promoted cell lysis is subject to many host cell factors, and for this reason, different cells have different sensitivities to Ad. To control for these differences when comparing between cell lines, we have made a relative comparison of Ad5 cytotoxic effect to oncolytic Ad cytotoxic effect (relative LD 50 ¼ LD 50Ad5 / LD 50OAS403 ). In this way, tumor selectivity can be assessed independent of natural Ad tropism. OAS403 was highly selective for killing a panel of tumor cell lines compared to nontumor cells (Fig 2) . Although OAS403 is attenuated in vitro in tumor cells compared to the single promoter virus E2F-E1A, the magnitude of the shift in LD 50 on tumor cells is lower than the LD 50 shift observed in nontumor cells. These results indicate that addition of the hTERT promoter to control E4 may lead to reduced potency for tumor cell killing, but this is offset by a notable protective effect on nontumor cell lines. Results in cultured primary human hepatocytes confirm that control of both E1A and E4 genes in a tumor-selective fashion can lead to less cytotoxicity in hepatocytes, a major target tissue of toxicity in vivo for systemically delivered Ad.
The mouse is a semi-permissive species for human adenoviral infection. 47 Although infectious viral particles are not produced, early gene expression can lead to viral DNA replication in the liver following i.v. administration. Oncolytic Ads are designed to selectively replicate in and kill tumor cells and spare nontarget cells. The SCID mouse study was designed to assess the control of OAS403 replication in nontarget tissue in vivo and compare it to an oncolytic Ad with a single promoter, E2F-E3, previously characterized in this SCID model. 4 Animal models allowing full evaluation of human oncolytic Ad selectivity do not currently exist because these viruses do not undergo efficient replication, packaging, and cell lysis, and spread in these models. However, many aspects of the viral life cycle can be studied in mice. For example, the Ad E1A promoter 4 and the human E2F-1 promoter 48 are both active in mouse cells. As in humans, E1A produced by Ad can have toxic effects in mice, including the development of adenoviral nuclear inclusions. [49] [50] [51] Furthermore, Ad DNA replication can occur in mouse cells in vivo. 47 At the doses used, SCID mice are sensitive to the replication-related toxicities associated with E1A expression and viral DNA replication. Repression of E4 expression is expected to decrease viral DNA replication and consequently E1A gene dosage. Thus, the SCID mouse model is an appropriate model in which to analyze the contribution of E4 to control the initial stages of viral replication control and subsequent toxicity in vivo. 10 12 vp/kg; n ¼ 10) alone or in combination with Doxil s at high dose (1 Â 10 12 vp/kg; n ¼ 10) or low dose (6 Â 10 11 vp/kg; n ¼ 10) was monitored (see Materials and methods). Another group was given Doxil s alone (n ¼ 10) i.v. at 9 mg/kg. A negative control group was injected with HBSS (n ¼ 9). Data are expressed as the mean tumor volume þ SEM. *Po0.01 by t-test for combination groups compared to all other groups, SD21.
The relevance of the mouse model for assessment of hTERT promoter control is uncertain. Alignment of the first 300 bp of the mTERT and hTERT promoter sequences reveals a number of conserved regions. 52 Relative to the A in the initiation codon, there is an Ebox at position À314 in the hTERT promoter and at À32 in the mouse promoter. In addition, there are two SP1-binding sites located at À168 and À134, which are highly conserved between mouse and human. A second E-box identified at À242 in the human promoter is not conserved in the mouse promoter. An NFKB site has been functionally identified in the mTERT promoter that is absent in the hTERT promoter. 53 Despite the general similarity in promoter sequence, there are some important differences in mTERT and hTERT regulation. Unlike humans, in which the expression of hTERT is limited to a small number of normal tissues, 25 mTERT expression is widely expressed at low levels in many adult tissues. 52 Despite the difference in expression pattern, adenoviral vectors using the hTERT promoter to drive LacZ or HSV-thymidine kinase genes had undetectable transgene expression in the livers of mice, 28, 30, 33 suggesting that activity of the hTERT promoter is low in normal mouse liver. This was not attributable to the inability of the hTERT promoter to use the mouse transcriptional machinery, since LacZ expression was seen in the mouse lung carcinoma cell line M109. 30 We found that OAS403 elicited significantly lower levels of E1A-related hepatotoxicity, E4 expression, and hexon DNA copy number relative to an oncolytic Ad without E4 control (E2F-E3). These results suggest that the attenuation of replication in normal liver can be further enhanced by additional control of E4 expression. While E1A RNA levels per viral genome in the mouse livers were similar between OAS403 and E2F-E3, we observed lower levels of E4 expression when the native E4 promoter was replaced with the hTERT promoter. This indicates that the hTERT promoter is selectively regulating E4 expression. Furthermore, control of E4 expression was associated with lower Ad DNA copy number and reduced hepatotoxicity. A direct comparison in efficacy between a single promoter virus and OAS403 was not made because of the high level of hepatotoxicity and unrestricted viral replication seen in liver following intravenous administration of E2F-E3 (Tables 1 and 2 ). While E2F-E1A was more potent than OAS403 in vitro and E2F-E3 was previously shown to be effective following intratumoral administration, the reduced tumor selectivity of a single promoter virus rendered it unsuitable for systemic administration. 4 The three doses of OAS403 evaluated in a Hep3B xenograft tumor model following i.v. administration were equally efficacious (Fig 6a) . Tumors isolated on study day 4 contained high levels of Ad genome copy number and high levels of E1A and E4 gene expression, which were similar at all doses and consistent with the observed lack of a dose response in antitumor efficacy (Fig 6a, Table 3 ). The high copy number in the liver confirms previous findings, indicating that liver is the major target organ for Ad distribution following i.v. administration. 54 The marked increase in copy number and E1A and E4 expression in the liver at the high dose was correlated with changes in toxicological end points such as an early transient decrease in platelet counts and an elevation in serum liver enzymes (Fig 6b, Table 3 ). At the high dose, there appears to be a loss of gene regulation and unrestricted viral DNA replication in liver. These nonlinear effects on selected parameters in the liver are consistent with a threshold effect, which has been previously reported for intravenously delivered replication-defective adenoviral vectors, 55, 56 and suggest that viral activity in the liver plays a role in the observed toxicities.
In a follow-up study, we determined the Ad genome copy numbers in liver and tumor at multiple time points following delivery of a single dose (Fig 7) . In this kinetic study, we showed that a time-dependent increase in Ad genome copy number occurs in Hep3B tumors but not livers. These results are consistent with an in situ increase in Ad DNA copies as a result of selective Ad replication in tumor. Furthermore, these changes in copy number in tumor correlate with the time-dependent inhibition of tumor growth observed in the efficacy study (Fig 6a) . In liver, the peak in copy number at 4 hours may reflect both hepatocyte transduction and Kupffer cell uptake of the input dose. The subsequent decrease in liver at 24 hours may reflect Ad elimination by Kupffer cells. 56 While there is a chronic level of Ad maintained in liver for the duration of the study, the kinetics do not suggest that significant Ad DNA replication is taking place in the liver compared to tumors, demonstrating the proofof-concept for systemically delivered tumor-selective oncolytic Ads.
The efficacy of OAS403 in a prostate carcinoma LNCaP model was very high, with a single i.v. dose of 3 Â 10 12 vp/kg eliciting complete tumor regressions in the majority of animals (Fig 8) . These in vivo antitumor results are not precisely predicted by in vitro cytotoxicity assays, which showed that LNCaP cells were actually less senstive than Hep3B cells to killing by both wild-type Ad5 and by OAS403. Clearly, some tumor models are more responsive to oncolytic Ads than others. This may result from not merely differences in sensitivity of the tumor cells to Ad, but also from features of tumor architecture which may interfere with virus spread, activity of selective promoters which may be impacted by factors present in vivo, tumor vascularity which may effect delivery of virus to tumor cells, or any number of other not yet well understood factors which limit or promote oncolytic Ad activity in vivo. The clinical utility of oncolytic Ads may be improved by a better understanding of these parameters. In the less-sensitive Hep3B in vivo model, we were able to improve the efficacy by combination with chemotherapy.
Combining OAS403 with Doxil s results in a significant enhancement in antitumor efficacy (Fig 9) . There is a strong potential for synergy between OAS403 and traditional chemotherapeutics. The synergy between oncolytic Ads and chemotherapeutic agents in preclinical models of lung cancer, 57 prostate cancer, 58 and hepatocellular carcinoma 59 has been demonstrated previously. Clinically, combination of 5-FU with oncolytic virus Addl1520 for liver cancer was well tolerated. 60 A controlled clinical trial in which recurrent head and neck cancer patients being treated with cisplatin and 5-FU were also treated with an oncolytic Ad demonstrated stasis in virally injected tumors, whereas all noninjected tumors treated with chemotherapy alone progressed. 11 In clinical trials, the response rate for tumors in patients treated with combinations improved compared to tumors in patients treated with chemotherapy alone. 13 There are several possible mechanisms underlying the synergy between virotherapy and chemotherapy. We have observed that Ad downregulates the expression of multidrug-resistant proteins like MRP in vitro (data not shown). This may lead to higher levels of the toxic drug in tumor cells and more efficient cell killing. Others have shown that some chemotherapy drugs promote adenoviral replication, which may account for the observed synergy between oncolytic Ads and chemotherapy drugs. 61 Combination of an oncolytic Ad with taxane causes enhanced p53 expression, which may result in increased p53-mediated apoptosis. 58 Finally, agents which induce cells to undergo apoptosis after capsid assembly have been shown to promote viral spread through tumors. 62 Overall, the evidence for synergistic effects between oncolytic Ad and chemotherapy is strong, but mechanisms are not yet understood.
In conclusion, we have constructed an oncolytic Ad, which is suitable for systemic administration and active in a majority of human cancers. This oncolytic Ad, which utilizes the E2F-1 and hTERT promoters to control E1A and E4 expression, respectively, was more selective than one with only E1A control. It was active in a panel of tumor cell lines in vitro, was less cytotoxic in cultured human hepatocytes, and was better tolerated following systemic administration in SCID mice. Using mouse xenograft tumor models, we demonstrated tumor-selective early gene expression, tumor-selective viral replication, and significant antitumor efficacy following systemic administration in mice. Combination with doxorubicin significantly enhanced antitumor efficacy. OAS403 is safe and effective when delivered systemically, and is a candidate for clinical application for the treatment of a broad range of human cancers including metastatic disease.
